In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

British Journal of Cancer

Volumn 73, Issue 11, 1996, Pages 1362-1365

  Tokuda, Y ^a   Ohnishi, Y ^b   Shimamura, K ^a,c   Iwasawa, M ^a   Yoshimura, M ^b   Ueyama, Y ^a,b,c   Tamaoki, N ^a   Tajima, T ^a   Mitomi, T ^a  

^a TOKAI UNIVERSITY   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Anti tumour effect; c erbB 2; Humanised monoclonal antibody; Severe combined immunodeficient mice

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; ONCOPROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE C ERB; PRIORITY JOURNAL; SCID MOUSE;

EID: 0029886350     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.259     Document Type: Article

References (28)

1. BASELGA J, TRIPATHY D, MENDELSOHN J, BENZ C, DANTIS L, MOORE J, ROSEN PP, HENDERSON IC, BAUGHMAN S, TWADDELL T AND NORTON L. (1995). Phase II study of recombinant human anti-HER2 monoclonal antibody (rhuMAb HER2) in stage IV breast cancer (BC): HER2-shedding dependent pharmacokinetics and antitumour activity (abstract). Proc. Am. Soc. Clin. Oncol., 14, 103.
2. HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA, 89, 4285-4289.
3. COUSSENS L, YANG-FENG TL, LIAO Y-C, CHEN E, GRAY A, MCGRATH J, SEEBURG PH, LIEBERMANN TW, SCHLESSINGER J, FRANKE U, LEVISON A AND ULLRICH A. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139.
4. DE POTTER CR, VAN DAELE S, VAN DE VIJVER MJ, PAUWELS C, MAERTENS G, DE BOEVER J, VANDEKERCKHOVE D AND ROELS H. (1989). The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology, 15, 315-326.
5. DREBIN JA, LINK VC, STERN DF, WEINBERG RA AND GREEN MI. (1985). Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41, 695-706.
6. FENDLY BF, WINGET M, HUDZIAK RM, LIPARI MT, NAPIER MA AND ULLRICH A. (1990). Characterization of monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50, 1550-1558.
7. HANCOCK MC, LANGTON BC, CHAN T, TOY P, MONAHAN JJ, MISCHAK RP AND SHAWVER LK. (1991). A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51, 4575-4580.
8. HARWERTH I-M, WELS W, MARTE BM AND HYNES NE. (1992). Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J. Biol. Chem., 267, 15160-15167.
9. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9, 1165-1172.
10. INABA M, TASHIRO T, KOBAYASHI T, SAKURAI Y, MARUO K, OHNISHI Y, UEYAMA Y AND NOMURA T. (1988). Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn. J. Cancer Res., 79, 517-522.
11. KASPRZYK PG, SONG SU, DI FIORE PP AND KING CR. (1992). Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res., 52, 2771-2776.
12. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50, 5184-5191.
13. KING CR, KRAUS MH AND ARONSON SA. (1985). Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science, 229, 974-976.
14. LARSON SM, BROWN JP, WRIGHT PW, CARRASQUILLO JA, HELLSTROM I AND HELLSTROM KE. (1983). Imaging of melanoma with I-131-labeled monoclonal antibodies. J. Nucl. Med., 24, 123-129.
15. MCCABE RP, PETERS LC, HASPEL MV, POMATO N, CARRASQUILLO JA AND HANNA JR MG. (1988). Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors. Cancer Res., 48, 4348-4353.
16. MOSMANN T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
17. OHNISHI Y, NAKAMURA H, YOSHIMURA M, TOKUDA Y, IWASAWA M, UEYAMA Y, TAMAOKI N AND SHIMAMURA K. (1995). Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody. Br. J. Cancer, 71, 969-973.
18. PRESS MF, CERDON-CARDO C AND SLAMON DJ. (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5, 953-962.
19. SCHROFF RW, FOON KA, BEATTY SM, OLDHAM RK AND MORGAN JR AC. (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., 45, 879-885.
20. SHAWLER DL, BARTHOLOMEW RM, SMITH LM AND DILLMAN RO. (1985). Human immune response to multiple injection of murine monoclonal IgG. J. Immunol., 135, 1530-1535.
21. SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SG, KEITH DE, LEVIN WJ, STUART SG, UDOVE J, ULLRICH A AND PRESS MF. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
22. STANCOVSKI I, HURWITZ E, LEITNER O, ULLRICH A, YARDEN Y AND SELA M. (1991). Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc. Natl Acad. Sci. USA, 88, 8691-8695.
23. HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47, 933-937.
24. TOKUDA Y, EBINA N AND GOLUB SH. (1989). The inhibitory effect of human α-interferon on the generation of lymphokine activated killer activity. Cancer Immunol. Immunother., 30, 205-212.
25. VAN DE VIJVER M, VAN DE BERSSELAAR R, DEVILEE P, CORNELISSE C, PETERSE J AND NUSE R. (1987). Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell Biol., 7, 2019-2023.
26. YAMAMOTO T, IKAWA S, AKIYAMA T, SEMBA K, NOMURA N, MIYAJIMA N, SAITO T AND TOYOSHIMA K. (1986). Similarity of protein encoded by human c-erbB-2 gene to epidermal growth factor receptor. Nature, 319, 230-234.
27. YARDEN Y AND ULLRICH A (1988). Growth factor receptor tyrosine kinases. Annu. Rev. Biochem., 57, 443-478.
28. YOKOTA J, YAMAMOTO T, TOYOSHIMA K, TERADA M, SUGIMURA T, BATTIFORA H AND CLINE MJ. (1986). Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet, 1, 765-767.